RecruitingPhase 2NCT07288333

Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization

Sponsor

Neurocrine Biosciences

Enrollment

120 participants

Start Date

Feb 16, 2026

Study Type

INTERVENTIONAL

Conditions

Schizophrenia

Summary

The primary objective for this study is to evaluate the efficacy of NBI-1117570 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults who warrant inpatient hospitalization.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called NBI-1117570 and a drug called Placebo for people with schizophrenia. The study is currently recruiting participants at 5 locations. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.